Table 2.
Vitamin 25(OH)D evaluation in enrolled subjects (Groups 1, 2, 3, and 4) using high-performance liquid chromatography-ultraviolet (HPLC-UV), enzyme-linked immunosorbent assay (EIA), and chemiluminescence immunoassay (Liaison®, Architect I1000®, and Lumipulse®) with respect to the gold standard liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Data are expressed as mean ± standard deviation.
| Groups | Sex | HPLC-UV (ng/mL) |
LC-MS/MS (ng/mL) |
Liaison (ng/mL) |
EIA (ng/mL) |
Architect (ng/mL) |
Lumipulse (ng/mL) |
|---|---|---|---|---|---|---|---|
| Group 1 | M | 13.7 ± 4.1 | 15.4 ± 4.3 | 16.0 ± 5.1 | 27.3 ± 6.1 | 16.3 ± 4.0 | 18.7 ± 5.3 |
| F | 14.1 ± 3.5 | 15.8 ± 3.7 | 16.3 ± 4.2 | 26.7 ± 6.2 | 16.7 ± 3.3 | 19.5 ± 5.5 | |
| Group 2 | M | 14.9 ± 4.7 | 16.6 ± 4.7 | 17.5 ± 5.9 | 25.8 ± 6.8 | 17.4 ± 4.4 | 20.0 ± 5.8 |
| F | 15.1 ± 5.7 | 16.4 ± 6.0 | 16.0 ± 6.8 | 28.9 ± 6.2 | 16.6 ± 5.6 | 19.3 ± 6.1 | |
| Group 3 | M | 17.3 ± 4.3 | 18.2 ± 3.2 | 19.8 ± 3.6 | 30.2 ± 6.2 | 19.6 ± 4.1 | 23.6 ± 5.2 |
| F | 18.5 ± 3.8 | 18.3 ± 3.6 | 19.9 ± 4.1 | 30.5 ± 5.9 | 19.1 ± 3.9 | 22.1 ± 4.8 | |
| Group 4 | M | 18.9 ± 4.2 | 19.1 ± 5.2 | 20.1 ± 4.8 | 30.7 ± 5.2 | 20.2 ± 4.5 | 23.1 ± 4.6 |
| F | 20.2 ± 4.5 | 21.5 ± 4.6 | 23.6 ± 4.5 | 29.6 ± 5.1 | 23.4 ± 3.7 | 26.9 ± 5.7 |